Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor wi... Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Show more
Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and...
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.5 | -25.3807106599 | 1.97 | 2.0153 | 1.45 | 2622187 | 1.66646297 | CS |
4 | -0.35 | -19.2307692308 | 1.82 | 2.59 | 1.45 | 991300 | 1.74411544 | CS |
12 | -2.05 | -58.2386363636 | 3.52 | 3.6192 | 1.38 | 1669532 | 2.22685775 | CS |
26 | -2.84 | -65.8932714617 | 4.31 | 4.7871 | 1.38 | 768496 | 2.2929321 | CS |
52 | -6.45 | -81.4393939394 | 7.92 | 22.35 | 1.38 | 1291554 | 8.56885023 | CS |
156 | -958.53 | -99.846875 | 960 | 1215 | 1.38 | 2020260 | 123.77049256 | CS |
260 | -6748.53 | -99.9782222222 | 6750 | 8182.5 | 1.38 | 1753624 | 325.33224558 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales